Ameriprise Financial Inc. Has $16.28 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Ameriprise Financial Inc. decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 450,261 shares of the specialty pharmaceutical company's stock after selling 95,794 shares during the period. Ameriprise Financial Inc. owned 0.82% of Supernus Pharmaceuticals worth $16,281,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after acquiring an additional 51,005 shares during the last quarter. Franklin Resources Inc. raised its position in Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after purchasing an additional 2,121 shares during the last quarter. Empowered Funds LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth $1,498,000. Smartleaf Asset Management LLC boosted its position in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after buying an additional 3,495 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN traded down $0.35 during trading on Thursday, reaching $32.28. 15,516 shares of the company's stock were exchanged, compared to its average volume of 485,618. The company's fifty day moving average price is $31.98 and its 200-day moving average price is $34.80. The firm has a market capitalization of $1.81 billion, a PE ratio of 30.24 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SUPN. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.